Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

The purpose of the study was to assess the prognosis of HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression and investigate the predictors of complete response. HER2-positive metastatic breast cancer patients who received long-term trastuzumab were included in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dogan, Izzet, Aydin, Esra, Khanmammadov, Nijat, Paksoy, Nail, Saip, Pinar, Aydiner, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232540/
https://www.ncbi.nlm.nih.gov/pubmed/37258548
http://dx.doi.org/10.1038/s41598-023-35715-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232540/
https://www.ncbi.nlm.nih.gov/pubmed/37258548
http://dx.doi.org/10.1038/s41598-023-35715-2

Ejemplares similares